ArticleJAMA2023

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

John R Sims et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.